Peptide Knowledge Center

Therapeutic Drugs for Autoimmune Diseases with Peptides

Most of the current treatments for autoimmune diseases are non-specific immunosuppressants by interfering with innate and acquired immune responses, and have strong side effects. Therefore, targeting specific molecular pathways and cells, specifically regulating the immune system, and rebuilding the body's immune tolerance mechanism is a new trend in the treatment of autoimmune diseases. Although the use of specific antigens to induce immune tolerance to treat autoimmune diseases can highly selectively inhibit the lymphocyte clones of specific antigens without affecting the normal immune function of the body, it overcomes the toxic and side effects of traditional chemical drugs


It has been successful in animal models of some diseases. However, complete antigen or protein immunity may cross-link IgE, thereby activating mast cells and basophils in allergic individuals, causing severe allergic reactions; or activating pathogenic B and T cells in patients with autoimmune diseases, exacerbate the disease. Therefore, identification of epitope peptides with therapeutic effects (only a small fragment of the full-length antigen), which can not only play a role in immunotherapy but also reduce adverse reactions, will be a new and promising therapeutic strategy. It has become a hot spot in the research on the prevention and treatment of autoimmune diseases. In animal models of various autoimmune diseases, peptide immunization has shown good therapeutic effects.


Synthetic peptides can interfere with a variety of autoimmune responses and have attracted more and more attention and become potential drug candidates for the treatment of autoimmune diseases. The introduction of pseudo-peptide bonds or reverse modification of the amino-terminus and carboxyl-terminus into the amino acid sequence of the polypeptide can increase the stability of the polypeptide drug and improve its biological activity; polypeptide therapy can avoid the allergic reaction caused by the immunogenicity of the full-length protein, with good safety. , has broad application prospects in autoimmune and chronic inflammatory diseases, but its mechanism of action has not been fully elucidated. Therefore, in future research, it is necessary to further study its mechanism of action and Toxic and side effects in the treatment process, improve the safety and therapeutic effect of polypeptide drugs for autoimmune diseases, and provide new targets for the development of anti-inflammatory drugs for autoimmune diseases


From Omizzur Biotech: Focus on custom peptide synthesis